Analyst Expectations for Castle Biosciences's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 12 analysts have published their opinion on Castle Biosciences (NASDAQ:CSTL) stock. The company has an average price target of $34.83, a decrease of 21.73% from the previous average price target of $44.50. The majority of the analysts are bullish on the stock.
July 07, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have given a lower average price target for Castle Biosciences, indicating a potential decrease in the stock price. However, the majority of the analysts are bullish on the stock.
The decrease in the average price target suggests that analysts expect the stock price to decrease. However, the fact that most analysts are bullish indicates that they believe the company has strong fundamentals and potential for growth, which could mitigate the expected decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100